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Abstract: The safety of cosmetics sold in Europe is based on the safety evaluation of each individual
ingredient conducted by those responsible for putting the product on the market. However, those
substances for which some concern exists with respect to human health (e.g., colorants, preservatives,
UV-filters, nanomaterials) are evaluated at the European Commission level by a scientific committee,
currently called the Scientific Committee on Consumer Safety (SCCS). According to the Cosmetics
Regulation (European Commission, 2009), it is prohibited in the European Union (EU) to market
cosmetic products and ingredients that have been tested on animals. However, the results of studies
performed before the ban continue to be accepted. In the current study, we evaluated the use of
in vitro methods in the dossiers submitted to the SCCS in the period between 2013 and 2016 based
on the published reports issued by the scientific committee, which provides a scientific opinion on
these dossiers. The results of this evaluation were compared with those of an evaluation conducted
four years previously. We found that, despite a slight increase in the number of studies performed
in vitro, the majority of studies submitted to the SCCS is still done principally in vivo and correspond
to studies performed before the ban.
Keywords: alternative methods; cosmetic ingredients; safety evaluation; animal ban; dossiers; SCCS;
in vitro; in vivo
1. Introduction
The safety evaluation of cosmetics in Europe is based on the evaluation of each individual
ingredient. Article 3 of the Cosmetics Regulation specifies that a cosmetic product made available on
the market shall be safe for human health when used under normal or reasonably foreseeable conditions
of use. In practice, cosmetic products have rarely been associated with serious health hazards, which,
however, does not mean that cosmetics are safe to use per se. Particular attention needs to be paid to
the long-term safety aspects, since cosmetic products may be used extensively over much of the human
lifespan and sensitive groups of the population such as children, old people, and pregnant women
may be involved. Therefore, the safety-in-use of cosmetic products has been established in Europe by
controlling the substances, their chemical structures, toxicity profiles, and exposure patterns.
For those substances for which some concern exists with respect to human health (e.g., colorants,
preservatives, UV-filters), the safety evaluation is conducted at the European Commission (EC) level
by the Scientific Committee on Consumer Safety (SCCS).
The SCCS was established in 2008 to replace the former Scientific Committee of Consumer
Products (SCCP). Before 1997, the opinions adopted by the Scientific Committee on Cosmetology
at the Commission’s request were included in EC-Reports. Between 1997 and 2004, all Scientific
Committee opinions were published on the Internet and can be accessed through the relevant
Committee’s Website. All SCCS opinions can be located via the ingredient’s category and the adoption
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date [1]. Since November 2015, the opinions have also been published in Regulatory Toxicology
and Pharmacology.
One of the responsibilities of the SCCS is to recommend a set of guidelines to be taken into
consideration by the cosmetic and raw material industry when developing studies to be used
in the safety evaluation of cosmetic substances. The SCCS evaluates the dossiers submitted by
industry through the Directorate General of Health and Food Safety (DG SANTE). The ingredients
evaluated by the SCCS correspond to those in the Annexes of Regulation; more specifically, substances
with restrictions in Annex III, and colorants, preservatives and UV-filters in Annexes IV, V and
VI, respectively.
The determination of the toxic potential of a cosmetic substance is based on a series of toxicity
studies and forms part of the hazard identification. Alternative methods to animal testing of cosmetic
ingredients have not been mandatory in Europe since March 2013, according to the Commission.
Traditionally, toxicological data relevant for man have been obtained by investigating the toxicological
profiles of the substances on animals, if possible using the same exposure route as in humans
(topical, oral or inhalation route). Toxicological studies are often performed by the oral route and then
the corresponding extrapolation to the dermal route should be done.
When the dossier of a cosmetic substance is submitted for evaluation by the SCCS, the manufacturer
should provide the Commission with information about acute toxicity (if available); irritation and
corrosivity to skin and eye; skin sensitization; dermal/percutaneous absorption; repeated dose toxicity;
mutagenicity/genotoxicity; carcinogenicity; reproductive toxicity; toxicokinetics; photo-induced
toxicity and human data as detailed in the notes of guidance of the SCCS revised in 2016 [2].
According to the Cosmetics Regulation (European Commission, 2009), it is prohibited in the EU
to market any cosmetic products and ingredients that have been tested on animals for most of their
human health effects, including acute toxicity. This means that the cosmetic industry needs to have
alternative approaches available to test the safety of ingredients of consumer products.
The use of animals in cosmetic testing was forbidden from March 2009, onwards, with the
exception of studies on repeat dose, which were permitted until March 2013. From this date,
new studies of old or new substances intended for cosmetic were required to be conducted
without animals.
In a previous paper, we studied the use of alternative methods in the dossiers submitted to
the SCCS in the period April 2009–March 2013, immediately prior to the ban. In the current study,
we compare the use of alternative methods in studies presented in the dossiers before and after the
complete ban in March 2013.
2. Materials and Methods
The study material consisted of SCCS opinions issued between April 2013 and March 2016 after
the nomination of SCCS new members. No confidential data were used, as all information came from
opinions downloaded from the Committee’s website. In the present study, only the full opinions
were considered; we did not take into account addenda or special opinions on a particular item,
such as sensitization.
Each opinion was analyzed for each different methodology in the toxicological section, recording
the procedure used and distinguishing between procedures based on in vivo or in vitro models.
The percentage of studies performed using non-animal models was compared to that of studies using
animal models and in some cases with human data.
A total of 41 dossiers were analyzed, 19 corresponding to hair dyes and 22 to other substances
including UV filters, fragrances, and preservatives, among other ingredients. The results obtained
were compared with those of the opinions published in the period 2009–2013 and other previously
published results [1].
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3. Results and Discussion
The SCCS opinions are currently organized into those for hair dyes, cosmetic ingredients and
nanomaterials, but, in the period evaluated in the previous paper [1], the opinions were organized
into those for fragrances, hair dyes, preservatives, UV-filters and other substances. In the current
paper, for comparative purposes, we combined all these categories. There were fewer SCCS opinions
in the period 2013−2016 than the previous period, as the later period was shorter, so, for comparative
purposes, we used percentage.
Studies performed with animals were considered acceptable if they were done before the ban
on animal use. The requirements for the use of in vivo and in vitro methods in the safety evaluation
of cosmetic ingredients performed by the SCCS are that the methods follow a guideline and were
conducted based on the principle of good laboratory practices (GLP). If a study does not satisfy these
criteria, then it is not considered by the SCCS and new data are required.
We have recorded the total number of studies performed in vivo, in vitro or in humans.
Some ingredients have been studied with different methodologies for a specific toxicological study.
3.1. Acute Toxicity
Studies of acute toxicity are not always necessary in the dossiers submitted to the SCCS but
were usually present in the dossiers supplied by industry, and, in most cases, were performed
in rats, mice and rabbits. The oral route was the most commonly employed route, but dermal
administration was also used, and, in a few cases, information about the inhalation route was also
supplied. All accepted methods for determining acute oral toxicity are based on in vivo experiments
after the single administration of a few doses and estimation of the dose causing the death in 50% of
the animals. The 3T3 Neutral Red Uptake cytotoxicity assay has been proposed to identify substances
not requiring classification as acute oral toxicants under EU regulations [3], but none of the dossiers
evaluated in the period 2013–2016 or 2009–2013 used this methodology.
3.2. Eye Irritation
In the dossiers submitted to the SCCS, almost all studies were performed on albino rabbits
and only a few used in vitro methods. However, there has been a slight increase in the use of
in vitro methods. The majority of the in vivo studies were performed on rabbits and followed the the
Organisation for Economic Co-operation and Development (OECD) 405 guideline, which was adopted
in 1981 and updated successively in 1987, 2002, and recently in 2012 [4]. Figure 1 shows the percentage
of studies performed to evaluate eye irritation in the two periods studied. It shows that there has been
a decrease in the number of studies performed in animals and in human volunteers in recent years.
In the case of human volunteers, the SCCS always indicates that it considers such studies unethical,
which could have led to the observed reduction.
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The study of eye irritation is one of the more classical studies performed on animals, usually rabbits
and was developed many years ago to evaluate cosmetics and cosmetic ingredients [5]. This method is
highly controversial and much efforts have been made to develop alternative methods [6].
Among the in vitro methods used in the dossiers of different ingredients presented to the SCCS for
evaluation, there is the isolated chicken eye (ICE) and the Bovine Corneal Opacity and Permeability Test
(BCOP), two validated methods appearing in the respective OECD guidelines [7,8]. Another method is
the Het-Cam, a non-validated method that is often used in the cosmetic industry due to its cheap cost [9].
Only one study was performed in ten human volunteers, involving an eyelash-waving product
containing thioglycolic acid. The human study did not conform to Good Clinical Practice (GCP),
but the overall requirements of GCP were fulfilled by the trial.
A method that uses reconstructed human cornea-like epithelium (RhCE), which closely mimics the
histological, morphological, biochemical and physiological properties of the human corneal epithelium,
has recently been included in the OECD guidelines. This test guideline describes an in vitro procedure
allowing the identification of chemicals (substances and mixtures) not requiring classification and
labelling for eye irritation or serious eye damage in accordance with UN Globally Harmonized System
of Classification and Labeling of Chemicals (UN GHS) [10]. Only two of the studies presented to the
SCCS used this methodology with one of the commercial three-dimensional RhCE tissue constructs
proposed by the guideline.
The in vitro studies included in the dossiers were performed after 2013, the year when the ban on
animal testing entered into force.
There is a need for alternative approaches to replace the in vivo rabbit Draize eye test for
evaluation of eye irritation of cosmetic ingredients given the animal ban and the potential contact
with the eyes of cosmetics designed for application around the eyes or formulations to be applied
on the head and accidentally contacted with eyes. Several assays have been developed, some of
which have undergone formal validation, but no single in vitro assay has been validated as a full
replacement for the rabbit Draize eye test. Each of the in vitro assays is related to a specific endpoint
of ocular irritation and gives only partial information on the mode of action of the material tested.
Thus, the weight-of-evidence (WoE) approach and results of multiple selected in vitro tests are needed
to accurately estimate the degree of eye irritation caused by cosmetic ingredients [9,11].
In the development of alternative methods, it is crucial to know which of the effects assessed
in the in vivo Draize eye test are responsible for driving the UN GHS and European Classification,
Labelling and Packaging (EU CLP) classification systems and the influence on the predictive capacity
of new in vitro methods. A number of key criteria should be taken into consideration when selecting
reference chemicals for the development, evaluation and/or validation of alternative methods and/or
strategies for serious eye damage/eye irritation testing [12]. Cosmetics Europe recently compiled
a database of Draize data used for past validation activities. An evaluation of the various in vivo
drivers of classification compiled in the database was performed to establish which of these were most
important from a regulatory point of view, and, from the results obtained, they suggested the need for
a critical revision of the UN GHS/EU CLP decision criteria for the Cat 1 classification of chemicals [13].
3.3. Skin Irritation
The accepted method of testing skin irritation was adopted in 1981 and updated in 2002 [14].
The method is based on the use of rabbits, but other species such as guinea pig and mouse have been
used to a lesser extent for the evaluation of cosmetic ingredients.
As in the case of eye irritation, there has been a decrease in the number of studies performed
in vivo and in human volunteers in recent years. The percentage of studies performed in vitro increased
from 5% to 20% between the two study periods and the percentage of studies on human volunteers
decreased (Figure 2).
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One of the in vitro methods used to test skin irritation is the rat skin Transcutaneous Electrical
Resistance test (TER), which is really an ex vivo method, because a laboratory animal (rat) is required
to obtain the skin with subsequent determination of the TER. This method was not considered in
the present study as an alternative method to animal testing and was not recorded in this context.
The method was adopted in 2004 by the OECD guidelines and updated in 2013 [15], but really it
determines skin corrosion rather than skin irritation.
The alternative method used in the studies for SCCS evaluation is the one based on reconstructed
human epidermis. The method was accepted in the OECD guidelines as OECD439 in 2010 and was
updated in 2013 and then in 2015 [16]. Taking the EpiskinTM method as an example, the SCCS expressed
concerns with regard to the potential interference with colour formation by reducing substances,
hair dyes and colorants, and the SCCS expressed the opinion that the modified Episkin™ method did
not provide sufficient proof that the 3-(4,5)-dimethyl-2-thiazolyl-2,5-diphenyl-2H-tetrazolium bromide
(MTT) test could be used as a suitable endpoint to test color ingredients/hair dye substances for their
potential skin irritant properties. A different endpoint, not involving optical density quantification,
should be envisaged [17]. A recent study recommended that HPLC/UPLC-spectrophotometry to
measure formazan should be included in the list of in vitro methods based on reconstructed human
epidermis, irrespective of the test system used and the toxicity endpoint evaluated, thus extending the
applicability of these test methods to strongly colored chemicals [18]. Another use of reconstructed
epidermis is for the evaluation of skin corrosion where the time of contact of the product with the
epidermis is shorter than for skin irritation [19].
As with eye irritation tests, Cosmetics Europe have developed a decision tree for skin irritation.
They concluded that the good correlation between in vitro and in vivo skin irritation assays, together
with the substantial in-house experience of these assays allows sufficient confidence in the outcomes
of these assays such that in-house safety assessments on new products can be made without the use
of animal testing. A decision tree for hazard assessment and labelling, using a weight of evidence
(WoE) approach, involves a step-wise evaluation of firstly, physicochemical characteristics, (Q)SAR
and existing data, to identify and rule out corrosive chemicals for further testing; secondly, an in vitro
corrosivity test; and, finally, an in vitro irritation test to distinguish between irritants and non-irritants.
In conclusion, evaluation of the skin irritation potential of new chemicals for use in cosmetics can be
confidently accomplished using only alternative methods [20].
3.4. Skin Sensitization
Skin sensitization is one of the principal concerns related to the use of cosmetics and is usually
associated with fragrances, preservatives and hair dyes [21–24].
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Most studies have been done in vivo and a lower percentage on humans using the patch test
method, to evaluate potential skin irritation caused by cosmetic ingredients (Figure 3). There has been
a slight increase in the percentage of studies performed using the patch test in recent years.
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The accepted animal testing methods for skin sensitization potential assessment include the
Mouse Local Lymph Node A say (LLNA) and it non-rad oac ve m dific tion (LLNA-DA and t
LLNA-BrdU ELISA) [25], the Guinea Pig M ximi ati Test by Magnusson nd Kligman (GPMT) and
the Buehler occluded patch t st in the guinea pig [26]. The most frequently used method was LLNA,
but guinea pigs were also used in different studies.
The Local Lymph Nod a say is considered a re uction and refinement method compared to
traditional guinea pigs tests since it provide advant g s in erms of animal welfare and was used until
M rch 2013, before the full ban on animal use. Since his date, it has no longer b en used to eval ate
cosmetic ingredients.
No studies on skin s sitization were performed in vitro, despite the fact that there are some
validated and OECD accepted methods, but these have only recently been accepted and the studies
considered in this paper wer performed efore 2013. The accepta ce of these methods sugg sts that,
in subs quent years, in vitro studies of skin sensitization will be pres nted to the SCCS for evalua ion.
One of the l st in vitro methods to be accep ed by the OECD is the In Vi ro kin Sensitisation or
human cell activ tion tes (h-CLAT), which is bas on activation of t e human monocytic leukaemia
cell line THP-1 [27] as developed previously [28]. Other were accep ed in 2015, including Test 442C,
the In Chemico Skin Sensitisation: Direct Peptide Reactivity Assay (DPRA) [29], which was d veloped
some years ago [30,31] and Test 442D: In Vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method [32].
This last method was proposed to demonstrate the second event that takes place in the sensitisation
mechanism occurring in the keratinocytes and includes i flammatory responses as well a gen
expres ion a sociated with specific cell signaling pathway such as th a tioxidant/electrophile
response element [33].
A recent paper has reviewed th different opportunity of the in vitro methods for the assessment
of contact sensitiz s [34]
3.5. Dermal Absorption
Dermal absorption is a well established in vitro method that is described in the OECD guidelines
and for which the SCCS have produced a special emorandum describing the requisites for the
evaluation of cosmetic ingredients, such as minimal number of replicates, and the amount of substance
applied on the Franz cells used in this test [35]. Despite the existence of an in vitro protocol, over the period
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being considered, some studies were performed on animals and human volunteers, with an increase in
the number of these studies and a decrease in the number of in vitro studies (Figure 4).Cosmetics 2017, 4, 30 7 of 14 
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The in vivo studies were done in rats, and only one used rabbits, accounting for 16% of the total
studies of dermal absorption. The SCCS recommends the use of human or pig for the in vitro method,
with human skin being preferred if available. Human skin from surgeries was the most used tissue.
One study used the chorioallantoic membrane as an alternative to Franz cells. This method was
described some years ago and the authors found the membrane to be similar to the buccal mucosa
in terms of permeation profile and permeability coefficient. For this reason, it is not appropriate for
studying dermal absorption [36].
Some dossiers did not include studies of dermal absorption, in which case an absorption of 100%
was assumed per default, as is indicated in the notes of guidance of the SCCS [37].
None of the studies used cultured or reconstructed human skin models because they have been
demonstrated to be inadequate due to their insufficient barrier function [38]. However, a recent paper
described a 3D model of congenital ichthyosis, representing severe epidermal barrier function defects,
which could be used to study dermal penetration [39].
Dermal absorption is an important factor in assessing the systemic toxicity of cosmetic ingredients.
Compounds with low dermal bioavailability do not need to be evaluated for repeated dose toxicity,
for which in vitro methods do not yet exist [40].
3.6. Genotoxicity
Studies of genotoxicity/mutagenicity in the dossiers presented to the SCCS showed an increase in
the percentage of in vitro methods in the period 2013–2016 compared to the previous period evaluated
(Figure 5).
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There are a number of validated and accepted methods for studying genotoxicity. In the case of
cosmetics, the SCCS has made a recommendation about which in vitro test should be used with the
exception of special cases for which the Ames test is not suitable, the SCCS recommends two assays
for the base level testing of cosmetic substances: the Bacterial Reverse Mutation Test or Ames test [41]
that test for gene mutations and the In Vitro Micronucleus Test [42] that test for both structural
(clastogenicity) and numerical (aneugenicity) chromosome aberrations [43].
If using both methods, there are four potential scenarios. If both tests are negative, then there
is no mutagenic potential and further testing is not necessary. If the Ames test is negative and the
in vitro micronucleus test is positive, then the substance may be considered an in vitro mutagen
and further testing may be essential to clarify the clastogenic potential of the substance. In this case,
either the Comet assay in mammalian cells [44] or in the 3D-reconstructed human skin model [45],
or the micronucleus test in the 3D-reconstructed human skin model should be considered [46].
If the Ames test is positive and the micronucleous test is negative, the substance may be considered
an in vitro mutagen. Further testing can be used such as an in vitro mammalian gene mutation test [47].
If the results from both tests are clearly positive in adequately performed tests, it is very likely that the
substance has mutagenic potential and further confirmatory tests are not necessary.
The SCCS recommends that both tests should be done, but looking at the different methods used
in the studies included in the dossiers, this is not always the case, and a considerable number of
in vivo studies were presented for safety evaluation of the different cosmetic ingredients because they
correspond to old studies performed before the ban.
However, as is shown in Figure 6, there has been an increase in the number of in vitro methods
used in studies. Among these studies, 54% only performed the Ames test, 7% only performed the
micronucleus test and 39% performed both as is shown in Figure 6. More studies used both tests after
the publication of the SCCS recommendation. Two studies in which the Ames test was positive and the
micronucleous test was negative subsequently performed the Comet assay in a 3D epidermis model
following this recommendation.
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A recent retrospective analysis of the mutagenicity/genotoxicity data of cosmetic ingredients has
revealed that the in vitro test showed a low specificity for cosmetic ingredients. The different assays
generated a high percentage of misleading positive results. As concluded by the authors of this study,
there is a need of better regulatory strategies for cosmetic ingredients [48].
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3.7. Carcinogenicity
Not all the dossiers included studies of carcinogenicity. Among the dossiers evaluated, the
studies of carcinogenesis were generally done in vivo, using rats, mice or rabbit via oral or
dermal administration.
As can be seen in Figure 7, the percentage of studies performed in vitro was very low with a slight
decrease between the two periods under consideration. The methods used for the in vivo studies did
not follow any guidelines, although there is an OECD guideline that was adopted in 1981 and was
recently reviewed [49].
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The in vitro studies in the dossiers under evaluation used the malignant transformation of
C31-1-mouse M2-fibroblasts assay, similar to in vitro Bhas 42 cell transformation assay. The latter cell
line was established by the transfection of the v-Ha-ras oncogene into the BALB/c 3T3 A31- 1-1 cell
line and represents one of the best-known cell transformation assays for screening single chemicals or
complex mixtures for carcinogenicity prediction [50]. The method has been validated [51] but has not
yet been accepted and only a draft of the OECD guideline is available [52].
A guidance document on the in vitro Bhas 42 cell transformation assay can be
downloaded at: http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/
JM/MONO(2016)1&docLa guage=En [53].
Another in vitro test for carci ogenicity that was not used in the documents of the dossiers
evaluated between 2009 and 2013, but was present in previous dossiers, is the Syrian hamster
embryo cell (SHE) assay. This test has been used, almost since its initial description, as an in vitro test
for determining the potential carcinogenicity of substances [54] and has been validated in various
studies [55].
3.8. Toxicokinetic Studies
Toxicokinetic studies consider different processes such as absorption, distribution, metabolism
and excretion (ADME). Many in vitro systems have their pitfalls, especially with respect to insufficient
reflection of the integrated in vivo physiological ADME conditions and the lack of fully validated
assays [56].
Comparison of the two periods evaluated in this paper revealed that the number of in vivo studies
has increased in recent years, but with a reduction in studies on human volunteers, and that there
has been no change in the use of in vitro studies (Figure 8). The small number of studies performed
in vitro can be attributed to the lack of validated methods on toxicokinetics.
The in vivo toxicokinetic studies were performed in different animals by different routes, mainly
oral and dermal. Few studies were performed on human volunteers after topical application of the
Cosmetics 2017, 4, 30 10 of 14
formulations. A small number of in vitro studies were conducted to demonstrate intestinal absorption
using CaCo-2 cells [57,58] and others to determine metabolism in the skin using HaCaT keratinocytes,
which have recently been demonstrated to be a model cell for the study of metabolomics effect of
nanoparticles [59]. None of the studies used reconstructed epidermis, despite the fact that this has
been demonstrated as a good strategy to study metabolism in vitro [60].
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The liver is the principal organ responsible for metabolism following absorption of a substance
and its arrival in blood circulation. Isolated hepatocytes were thus used as it has been demonstrated
that appropriate toxicokinetic information can be generated based solely on in vitro data, with the
resulting data being in the same order of magnitude as those published for human volunteers [61].
3.9. Phototoxicity
Studies of phototoxicity were performed in the case of products that are particularly designed
for exposure to sun radiation, such as UV filters but also for other products such as some hair dyes,
preservatives, etc. Only 13 ingredients, which represents 32% of the products evaluated were studied
for phototoxicity. Compared to the previous period of evaluation, the more recent period showed
a decrease in the number of studies performed in vitro (Figure 9).
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The in vitro method used to evaluate phototoxicity is based on the uptake of neutral red by the
fibroblast cell line 3T3. This method has been validated and accepted in the OECD guidelines [62].
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4. Conclusions
Based on the European ban on the use of animals to evaluate the safety of cosmetic ingredients
that entered into force in March 2013, toxicological studies should be performed in vitro. However,
the safety evaluation can be based on in vivo studies performed before the European ban on the use
of animals. Comparison of the evaluations of the different cosmetic ingredients performed by the
SCCS during the period 2013–2016 and 2009–2013 revealed a slight increase in the use of some in vitro
methods but not as much as expected. The reason for this is that many of the ingredients evaluated
were not new, and so the studies were based on tests conducted before the ban. The SCCS evaluates
certain cosmetic ingredients more than once and then old toxicological data are described, together
with the new data and for this reason there is a slight increase in the percentage of in vitro studies.
Despite the old studies are considered with the new ones, the more relevant observation is the use of
different in vitro methods.
Dossiers are a compilation of existing data and only if a test is not of enough quality or missing is
the new data required by the SCCS. New data corresponding to studies on animals are accepted if
they are performed before 2013. However, some in vitro studies were performed after 2013 and this
explains the slight increase in the use of alternative methodologies. The recent acceptance of different
alternative methods for skin sensitization should result in an increase in the number of such studies in
the dossiers presented by the industry for evaluation in the next few years. A great effort is done by
researchers to develop new in vitro methods and is done by industry to implement these new methods
for the evaluation of cosmetic ingredients. After the ban, new ingredients should be studied without
animals using in vitro, in chemico or by computational tools such as QSAR only.
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